• Advancing In Vitro Drug Response Evaluation in Cancer Resear

  2026-04-28

  Schwartz's dissertation redefines how in vitro drug responses are measured in cancer research by distinguishing between cell proliferation inhibition and cell death. This approach enhances the interpretability of apoptosis and viability assays, informing more precise evaluation of compounds such as Everolimus (RAD001).

• TaqI Restriction Endonuclease: Rapid DNA Digestion Protocols

  2026-04-28

  TaqI Restriction Endonuclease (SKU K3053) addresses the need for rapid and efficient sequence-specific DNA cleavage in plasmid, PCR, and genomic workflows. Its fast digestion capability streamlines molecular cloning and analysis but is not intended for diagnostic or clinical applications. Researchers requiring quick, reproducible sticky-end generation will benefit most from this tool.

• GLI2 Drives Tumor Immune Evasion via WNT–Prostaglandin Cross

  2026-04-27

  This study uncovers the pivotal role of GLI2 in orchestrating tumor immune evasion and resistance to immune checkpoint blockade by coordinating WNT ligand production and prostaglandin signaling. These insights identify GLI2 as a mechanistically actionable node for reversing immune suppression and overcoming immunotherapy resistance in cancer.

• Ceftazidime: Translational Insights for Gram-Negative Resist

  2026-04-27

  This thought-leadership article explores the evolving landscape of Gram-negative resistance, highlighting the mechanistic strengths and translational opportunities of Ceftazidime. Drawing on recent research, including the dynamics of carbapenemase-encoding genes in Enterobacter cloacae, it provides strategic guidance for researchers navigating complex resistance patterns, with a focus on workflow design, experimental rigor, and the future of antibiotic stewardship.

• Optimizing Western Blot Sensitivity with Enhanced ECL Detect

  2026-04-26

  The ECL Chemiluminescent Substrate Detection Kit (Enhanced) from APExBIO delivers ultra-sensitive, low-background protein detection—ideal for challenging western blot applications, including resistance mechanism research and low-abundance targets. Its compatibility and streamlined protocol empower rapid assay deployment and reproducible results across experimental scales.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-04-25

  Schwartz's dissertation introduces a rigorous framework for distinguishing between proliferative arrest and cell death in in vitro drug response assays. By clarifying the interpretation of relative versus fractional viability, the work enhances the reliability and translational value of preclinical cancer drug evaluation.

• Golgi-Tracker Green: Precision Sphingolipid Metabolism Imagi

  2026-04-24

  Discover how Golgi-Tracker Green, a BODIPY FL-labeled C5-ceramide probe, enables high-fidelity live-cell Golgi apparatus imaging and advanced sphingolipid metabolism studies. This article delivers unique mechanistic depth and assay optimization strategies beyond existing protocols.

• VX-661 for F508del CFTR Correction: Variant-Specific Rescue

  2026-04-24

  Explore how VX-661, a leading F508del CFTR corrector, enables variant-specific rescue in cystic fibrosis research. This article uncovers the interplay between molecular chaperones and corrector efficacy, offering unique, actionable perspectives for assay optimization.

• Berberine Hydrochloride: Precision Modulation of Cell Death

  2026-04-23

  Discover how Berberine Hydrochloride enables targeted modulation of apoptosis, pyroptosis, and ferroptosis in metabolic and cancer research models. This article delivers advanced, method-focused insights and uncovers new opportunities for assay optimization with Berberine Hydrochloride.

• EZ Cap™ Human PTEN mRNA: Transforming Tumor Suppressor Studi

  2026-04-23

  EZ Cap™ Human PTEN mRNA empowers precision cancer research and gene therapy by combining Cap 1 structure and robust poly(A) tailing for unmatched stability and translation. Novel workflows, including nanoparticle-based delivery, unlock high-fidelity tumor suppressor restoration and advanced immunotherapy investigations.

• 3X (DYKDDDDK) Peptide: Precision Affinity Purification Unloc

  2026-04-22

  The 3X (DYKDDDDK) Peptide streamlines the purification and detection of recombinant proteins with unparalleled sensitivity and flexibility. By leveraging its trivalent, hydrophilic design, researchers can optimize workflows for challenging applications, from metal-dependent ELISA to protein crystallization and high-throughput structural biology.

• Sequencing Therapies in Waldenström Macroglobulinemia: Genom

  2026-04-22

  This article reviews recent advances in the sequencing of therapies for Waldenström macroglobulinemia (WM), focusing on how genomic profiling—particularly MYD88 and CXCR4 mutations—informs optimal treatment selection. The reference study highlights the clinical relevance of mutation-guided regimens and emerging roles for CXCR4 antagonists, including potential applications in challenging patient subgroups.

• MK-2206 dihydrochloride: Precision PI3K/Akt/mTOR Inhibition

  2026-04-21

  MK-2206 dihydrochloride empowers researchers to dissect the PI3K/Akt/mTOR axis in cancer, bone, and metabolic studies with nanomolar precision. This guide details actionable workflows, troubleshooting tactics, and translational tips, bridging breakthrough O-GlcNAcylation insights with practical apoptosis and metabolic assays.

• Morin: Applied Protocols and Innovations in Mitochondrial Re

  2026-04-21

  Morin (2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one) empowers researchers with both mechanistic insight and advanced assay flexibility—serving as a unique, high-purity natural flavonoid for mitochondrial, metabolic, and fluorescent probe applications. Recent studies reveal Morin’s targeted inhibition of adenosine 5′-monophosphate deaminase, making it indispensable for energy metabolism modeling and disease research.

• Surfactant-Derived LNPs Enable Efficient mRNA Delivery to Ma

  2026-04-20

  This study introduces a dual-component lipid nanoparticle (LNP) system based on surfactant-derived ionizable lipids and fusogenic lipids for mRNA delivery to macrophages. The innovation addresses challenges in non-viral delivery to hard-to-transfect immune cells, with implications for research in gene regulation, immunotherapy, and mRNA-based technologies.

406 records 17/28 page Previous Next First page 上5页 1617181920 下5页 Last page